IMMEDIATE-RELEASE NIFEDIPINE LABELING WILL WARN AGAINST OFF-LABEL USES, FDA INDICATES FOLLOWING CALCIUM CHANNEL BLOCKER ADVISORY COMMITTEE REVIEW

Immediate-release nifedipine product labeling will be changed to warn of potential safety problems with off-label use in hypertension and other conditions, FDA said following the Cardiovascular & Renal Drugs Advisory Committee review of calcium channel blocker safety concerns Jan. 25.